US Patent 9630922 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
Patent 9630922 was granted and assigned to FORMA Therapeutics on April, 2017 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 9630922 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
